Neurocrine biosciences presents new post-hoc analysis of ongentys® (opicapone) capsules effect on comt activity at the 2022 mds international congress

San diego , sept. 15, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today will present data on the effects of ongentys® (opicapone) capsules on soluble-catechol-o-methyltransferase (s-comt) enzyme inhibition.
NBIX Ratings Summary
NBIX Quant Ranking